佰金生命科学(01466)完成发行4000万股 净筹约1910万港元

Core Viewpoint - Baijin Life Sciences (01466) has completed the prerequisites for a subscription agreement, with the completion date set for November 28, 2025, and will issue a total of 40 million subscription shares at a price of HKD 0.48 per share [1] Financial Summary - The total amount raised from the subscription is HKD 19.2 million, with a net amount of approximately HKD 19.1 million after expenses [1] - It is expected that 60% of the net proceeds will be used to repay bank loans, other borrowings, and other payables, while the remaining 40% will be allocated for general operating expenses, including audit and professional fees, salaries, and rent payments [1]